The present observational study aimed to evaluate the clinical effectiveness of vildagliptin with metformin in Korean patients with type 2 diabetes mellitus (T2DM). Data were pooled from the vildagliptin postmarketing survey (PMS), the vildagliptin/metformin fixed drug combination (DC) PMS, and a retrospective observational study of vildagliptin/metformin (fixed DC or free DC). The effectiveness endpoint was the proportion of patients who achieved a glycemic target (HbA1c) of ≤7.0% at 24 weeks. In total, 4303 patients were included in the analysis; of these, 2087 patients were eligible. The mean patient age was 56.99 ± 11.25 years. Overall, 58.94% patients achieved an HbA1c target of ≤7.0% at 24 weeks. The glycemic target achievement rate was significantly greater in patients with baseline HbA1c < 7.5% versus ≥7.5% (84.64% versus 43.97%), receiving care at the hospital versus clinic (67.95% versus 52.33%), and receiving vildagliptin/metformin fixed DC versus free DC (70.69% versus 55.42%). Multivariate logistic regression analysis indicated that disease duration (P<0.0001), baseline HbA1c (P<0.0001), and DC type (P=0.0103) had significant effects on drug effectiveness. Vildagliptin plus metformin appeared as an effective treatment option for patients with T2DM in clinical practice settings in Korea.
Bibliographical noteFunding Information:
This study was funded by Novartis Pharma Korea Ltd. The article processing charges for this publication were funded by Novartis Korea Ltd., Seoul, Republic of Korea. The authors would like to thank Rangan Gupta of Novartis Healthcare Private Limited, Hyderabad, India, for the technical support.
© 2017 Sunghwan Suh et al.
All Science Journal Classification (ASJC) codes
- Endocrinology, Diabetes and Metabolism